Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety

Author： Yadav Rahul   France Michael   Younis Naveed   Hama Salam   Ammori Basil J   Kwok See   Soran Handrean  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.9, 2012-06, pp. : 1345-1362

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Extended-Release Niacin (Nicotinic Acid)/Laropiprant

By Perry Caroline M.  

Drugs, Vol. 69, Iss. 12, 2009-08 ,pp. : 1665-1679

Adis International

Access to resources Recommend Favorite

Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia: The OCEANS Study

By Karas Richard H.  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 2, 2008-01 ,pp. : 69-81

Adis International

Access to resources Recommend Favorite

Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

By Bays Harold E.  

American Journal of Cardiovascular Drugs, Vol. 12, Iss. 3, 2012-06 ,pp. : 197-206

Adis International

Access to resources Recommend Favorite

Niaspan: managing hyperlipidaemia with extended-release niacin

By Bradley D.  

Pharmaceutical Science & Technology Today, Vol. 3, Iss. 8, 2000-08 ,pp. : 262-263

Elsevier

Access to resources Recommend Favorite

Extended-release niacin for modifying the lipoprotein profile

By Guyton John R  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1385-1398

Informa Healthcare

Access to resources Recommend Favorite